AbCellera Biologics (ABCL) News Today $2.97 +0.03 (+1.02%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period AbCellera Biologics Inc. (NASDAQ:ABCL) most popular amongst individual investors who own 36% of the shares, institutions hold 29%January 20 at 12:48 PM | finance.yahoo.comAbCellera Biologics (NASDAQ:ABCL) Trading Up 10.5% - Should You Buy?AbCellera Biologics (NASDAQ:ABCL) Stock Price Up 10.5% - Here's WhyJanuary 17 at 8:39 AM | marketbeat.comAbCellera Biologics Inc. (ABCL): A Bull Case TheoryJanuary 17 at 8:15 AM | insidermonkey.comAbCellera Biologics (NASDAQ:ABCL) Stock Price Down 6.7% - What's Next?AbCellera Biologics (NASDAQ:ABCL) Stock Price Down 6.7% - Here's What HappenedJanuary 16, 2025 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Trading Up 10.5% - What's Next?AbCellera Biologics (NASDAQ:ABCL) Trading 10.5% Higher - Still a Buy?January 15, 2025 | marketbeat.comAbbVie, AbCellera expand collaboration into T-cell engagersJanuary 15, 2025 | msn.comAbCellera Biologics (NASDAQ:ABCL) Trading Down 6.7% - Time to Sell?AbCellera Biologics (NASDAQ:ABCL) Stock Price Down 6.7% - Time to Sell?January 14, 2025 | marketbeat.comGeode Capital Management LLC Sells 201,213 Shares of AbCellera Biologics Inc. (NASDAQ:ABCL)Geode Capital Management LLC lowered its stake in shares of AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) by 63.9% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 113,653 shares of tJanuary 14, 2025 | marketbeat.comKeyCorp Cuts AbCellera Biologics (NASDAQ:ABCL) Price Target to $4.00January 11, 2025 | americanbankingnews.comAbCellera price target lowered to $4 from $5 at KeyBancJanuary 8, 2025 | markets.businessinsider.comAbCellera Biologics (NASDAQ:ABCL) Given New $4.00 Price Target at KeyCorpKeyCorp decreased their target price on shares of AbCellera Biologics from $5.00 to $4.00 and set an "overweight" rating on the stock in a research report on Wednesday.January 8, 2025 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Stock Price Down 7.9% - What's Next?AbCellera Biologics (NASDAQ:ABCL) Stock Price Down 7.9% - Time to Sell?January 8, 2025 | marketbeat.comIs AbCellera Biologics Inc. (ABCL) Among the Best Canadian Penny Stocks to Buy According to Analysts?January 7, 2025 | insidermonkey.comIs AbCellera Biologics Inc. (ABCL) Among the Best Canadian Penny Stocks to Buy According to Analysts?January 7, 2025 | msn.comAbCellera Biologics (NASDAQ:ABCL) Trading 7.2% Higher - Here's WhyAbCellera Biologics (NASDAQ:ABCL) Shares Up 7.2% - Time to Buy?January 2, 2025 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Trading Down 6% - Should You Sell?AbCellera Biologics (NASDAQ:ABCL) Stock Price Down 6% - Should You Sell?December 30, 2024 | marketbeat.comAbCellera Biologics: Still A Concept StockDecember 23, 2024 | seekingalpha.comIs AbCellera Biologics (NASDAQ:ABCL) In A Good Position To Invest In Growth?December 22, 2024 | au.finance.yahoo.comAbCellera Biologics (NASDAQ:ABCL) Stock Price Up 3.3% - Still a Buy?AbCellera Biologics (NASDAQ:ABCL) Trading Up 3.3% - What's Next?December 20, 2024 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Shares Gap Up - Should You Buy?AbCellera Biologics (NASDAQ:ABCL) Shares Gap Up - What's Next?December 13, 2024 | marketbeat.comWalleye Capital LLC Purchases Shares of 256,881 AbCellera Biologics Inc. (NASDAQ:ABCL)Walleye Capital LLC purchased a new stake in shares of AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 256,881 shares of the company's stock, valued at approximately $668,000. Walleye CaDecember 8, 2024 | marketbeat.comAbCellera Biologics Inc. (NASDAQ:ABCL) Stock Position Lowered by PDT Partners LLCPDT Partners LLC lessened its holdings in shares of AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) by 73.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 64,304 shares of theDecember 5, 2024 | marketbeat.comAbCellera to Present at Upcoming Investor Conferences in December and JanuaryNovember 21, 2024 | businesswire.comGSA Capital Partners LLP Has $629,000 Position in AbCellera Biologics Inc. (NASDAQ:ABCL)GSA Capital Partners LLP boosted its holdings in shares of AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) by 991.3% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 241,866 shares of the company's stock after acquirNovember 19, 2024 | marketbeat.comAbCellera Biologics Inc. (NASDAQ:ABCL) Position Trimmed by Baillie Gifford & Co.Baillie Gifford & Co. reduced its holdings in AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) by 41.1% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 12,894,703 shares of the company's stock after selling 9,016,311 shares during the quNovember 13, 2024 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Sees Strong Trading Volume - Should You Buy?AbCellera Biologics (NASDAQ:ABCL) Sees Unusually-High Trading Volume - What's Next?November 11, 2024 | marketbeat.comBloom Burton Has Negative Outlook for ABCL FY2024 EarningsAbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) - Stock analysts at Bloom Burton reduced their FY2024 earnings per share estimates for shares of AbCellera Biologics in a report issued on Tuesday, November 5th. Bloom Burton analyst D. Martin now anticipates that the company will post earningsNovember 8, 2024 | marketbeat.comAbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024November 7, 2024 | theglobeandmail.comAbCellera Biologics Inc. (NASDAQ:ABCL) Just Reported And Analysts Have Been Cutting Their EstimatesNovember 7, 2024 | finance.yahoo.comAbCellera Biologics (ABCL) Gets a Buy from Truist FinancialNovember 7, 2024 | markets.businessinsider.comFY2024 Earnings Estimate for ABCL Issued By Leerink PartnrsAbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) - Stock analysts at Leerink Partnrs lowered their FY2024 earnings per share (EPS) estimates for shares of AbCellera Biologics in a research note issued to investors on Tuesday, November 5th. Leerink Partnrs analyst P. Souda now expects that theNovember 7, 2024 | marketbeat.comAbCellera Biologics Third Quarter 2024 Earnings: Misses ExpectationsNovember 7, 2024 | finance.yahoo.comStifel Nicolaus Sticks to Their Buy Rating for AbCellera Biologics (ABCL)November 7, 2024 | markets.businessinsider.comAbCellera Biologics (ABCL) Receives a Hold from Benchmark Co.November 7, 2024 | markets.businessinsider.comAbCellera Biologics (NASDAQ:ABCL) Receives "Hold" Rating from BenchmarkBenchmark reaffirmed a "hold" rating on shares of AbCellera Biologics in a research report on Tuesday.November 5, 2024 | marketbeat.comQ3 2024 Abcellera Biologics Inc Earnings CallNovember 5, 2024 | uk.finance.yahoo.comAbCellera Biologics (NASDAQ:ABCL) Earns Buy Rating from Stifel NicolausStifel Nicolaus reissued a "buy" rating and set a $12.00 price target (down previously from $14.00) on shares of AbCellera Biologics in a research report on Tuesday.November 5, 2024 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Shares Gap Down After Earnings MissAbCellera Biologics (NASDAQ:ABCL) Shares Gap Down on Disappointing EarningsNovember 5, 2024 | marketbeat.comAbCellera Biologics Inc. (NASDAQ:ABCL) Q3 2024 Earnings Call TranscriptNovember 5, 2024 | msn.comAbCellera Biologics (NASDAQ:ABCL) Issues Earnings ResultsAbCellera Biologics (NASDAQ:ABCL - Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.17) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.03). AbCellera Biologics had a negative net margin of 463.77% and a negative return on equity of 13.40%. The firm had revenue of $6.51 million during the quarter, compared to analyst estimates of $8.95 million. During the same quarter in the previous year, the business earned ($0.10) EPS.November 5, 2024 | marketbeat.comAbCellera Biologics Reports Q3 2024 Financial ResultsNovember 5, 2024 | markets.businessinsider.comAbCellera Biologics Inc (ABCL) Q3 2024 Earnings Call Highlights: Navigating Challenges with ...November 5, 2024 | finance.yahoo.comAbCellera Biologics Expands Partnership and Advances PipelineNovember 5, 2024 | markets.businessinsider.comAbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call TranscriptNovember 4, 2024 | seekingalpha.comAbCellera Biologics Inc. 2024 Q3 - Results - Earnings Call PresentationNovember 4, 2024 | seekingalpha.comAbCellera Biologics Inc (ABCL) Q3 2024: Everything You Need To Know Ahead Of EarningsNovember 1, 2024 | finance.yahoo.comAbCellera Biologics (ABCL) Set to Announce Quarterly Earnings on MondayAbCellera Biologics (NASDAQ:ABCL) will be releasing earnings after the market closes on Monday, November 4, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=631907)October 28, 2024 | marketbeat.comAbCellera to Present at Upcoming Investor Conferences in November 2024October 22, 2024 | businesswire.comAbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024October 18, 2024 | theglobeandmail.comIs AbCellera Biologics Inc. (ABCL) the Penny Stock with the Biggest Upside Potential According to Analysts?October 16, 2024 | msn.com Get AbCellera Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABCL and its competitors with MarketBeat's FREE daily newsletter. Email Address ABCL Media Mentions By Week ABCL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ABCL News Sentiment▼0.540.44▲Average Medical News Sentiment ABCL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ABCL Articles This Week▼83▲ABCL Articles Average Week Get AbCellera Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABCL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Immunovant News Today Crinetics Pharmaceuticals News Today Avidity Biosciences News Today PTC Therapeutics News Today Rhythm Pharmaceuticals News Today Denali Therapeutics News Today Xenon Pharmaceuticals News Today ACADIA Pharmaceuticals News Today Vericel News Today MorphoSys News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ABCL) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbCellera Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbCellera Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ABCL Stock Alerts